|Day Low/High||171.84 / 172.98|
|52 Wk Low/High||109.16 / 165.16|
Let's go over five excuses so you know and are armed with them when they are used and make you faint and weak-handed.
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
In this market, winning stocks 'stick out like a sore thumb.'
This is how you can tell which camp is winning and which is losing in this time of Covid-contradiction.
Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.
The smallish clinical-stage vaccine company looks like a trade, not an investment, and might be approached as an option play.
What if the market is simply pricing in a quarter that had already been priced out?
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
I would wait until the next down day, and there will be one.
That's the really good news about why we could bounce back so quickly from Thursday's debacle.
The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.
We're cheering what may be an aberration, a bullish employment number. We'll take what it brings - a wholesale shift in what we're buying and what we're selling to fund it.
The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
I'm long this name, as I am several of the others involved. Will I add on a day like this?
Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.
The broad market may be soft for another week but if I find more stocks in a similar position as JNJ I won't see a reason to join the bear camp.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
Let's look at the stocks that will get crushed and that you can't touch right now.
I have always liked the aggressive management.
Don't pigeon hole yourself into a certain pattern of action when you see opportunities.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.